Must fraud claims identify specific allegations against each corporate defendant? State v. Watson Pharmaceuticals Inc. Explained

The Utah Court of Appeals recently addressed an important pleading requirement in fraud cases involving multiple corporate defendants in State v. Watson Pharmaceuticals Inc. The decision reinforces that plaintiffs must particularize their fraud allegations against each individual defendant, even when those defendants are related corporate entities.

Background and Facts

The State of Utah brought civil actions against numerous pharmaceutical companies for allegedly submitting inflated Average Wholesale Prices to the Medicaid program. This practice resulted in over-reimbursement to physicians and pharmacists, allowing drug companies to market the “spread” between inflated and actual prices. The State sued three Watson entities—Watson Pharmaceuticals Inc., Watson Laboratories Inc., and Watson Pharma Inc.—but pleaded against them collectively as “Defendant Watson” rather than identifying specific fraudulent acts by each entity.

Key Legal Issues

The central issue was whether the State’s collective pleading satisfied Rule 9(c) of the Utah Rules of Civil Procedure, which requires fraud to be pleaded “with particularity.” Under the Utah Supreme Court’s decision in State v. Apotex Corp., plaintiffs must provide “particular details of a scheme to submit false claims paired with reliable indicia that lead to a strong inference that claims were actually submitted by each defendant.”

Court’s Analysis and Holding

The court of appeals affirmed the dismissal, rejecting the State’s argument that the Watson defendants were sufficiently identified through National Drug Code numbers containing unique labeler codes. The court found three fatal flaws: (1) the State failed to demonstrate that the NDC numbers actually corresponded to the named defendants, (2) the State never informed the district court about the significance of the labeler codes, and (3) the State continued to plead collective responsibility for fraudulent reporting even if individual drugs could be linked to specific defendants. The court also upheld the dismissal with prejudice, noting the State had received multiple opportunities to amend its complaint and specific guidance from the Utah Supreme Court.

Practice Implications

This decision emphasizes that corporate separateness requires individualized fraud allegations against each defendant, regardless of common ownership or control. Practitioners must avoid “guilt-by-association” theories and provide specific representative examples of fraudulent conduct for each corporate entity. When relying on coded information like product numbers to identify defendants, the pleading must explicitly explain the significance of such codes rather than leaving courts to decipher hidden meanings.